Taken together, our study shows that infliximab treatment not only affect systemic inflammation but also associate with changes in inflammatory markers in the CSF of arthritis patients, which may help explain the ability ofinfliximab and other TNF-blocking agents to relieve CNS-related symptoms. The gene discussed is TNF; the disease is Arthritis.